The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.



Latest Headlines

Latest Headlines

Pfizer funds Canadian CME, prompting outcry

As some big-name hospitals and drugmakers back away from industry-funded medical education, the Canadian Medical Association has anted up. The CMA has teamed up with Pfizer on a nationwide

Pfizer's turning over a new leaf, Kindler vows

A week after testing his "let's follow the rules" message in the U.K., Pfizer chief Jeffrey Kindler (photo) has brought it home to the U.S. And this time, he addressed the elephant in the room

For security, Pfizer watches suppliers

"Do not enter into supply agreements with companies that do not meet acceptable standards, and terminate agreements with companies that do not maintain acceptable standards." So says Gerry

Pfizer Japan staffs up for brand, generic launches

As Pfizer lays off and shuts down in the U.S. and Europe, it will be beefing up big-time in Japan. Tapped today to lead Pfizer Japan, Ichiro Umeda told a press briefing that no jobs will be cut in

Jumping into rare diseases, Pfizer inks $115M Protalix deal

Pfizer is plunking down $60 million upfront and promising up to $55 million in milestones to license the worldwide rights to Protalix's drug for Gaucher disease--a move the puts the global pharma

Should Pfizer warn state on Pearl River layoffs?

Workers at Pfizer Pearl River in New York worry that the company is trying to skirt the law by laying off employees in dribs and drabs so they don't have to notify the state. Report | Report

Scottish clinic to test Dimebon

Glasgow Memory Clinic (GMC) is enrolling patients to test Dimebon-a promising candidate to treat Alzheimer's that might help improve a patient's memory, cognition and the ability to care for him or

Merger distracts Pfizer from biotech incubator

In 2007 Pfizer undertook a new project. The pharma giant pledged to invest $50 million over five years to help start-up biotechs get going at the company's incubator in La Jolla, CA. Pfizer hoped to

Kindler advises executive soul-searching

Pfizer CEO Jeff Kindler (photo) won praise in the U.K. yesterday for lecturing his fellow executives about public trust. "At last an executive that gets it," the Telegraph reported after Kindler's

Pfizer, DNDi to tackle tropical diseases

Pfizer and the Drugs for Neglected Diseases initiative (DNDi) recently announced that they have signed an agreement that will potentially lead to the discovery of compounds to treat human African